SG Americas Securities LLC Trims Stock Holdings in Alector, Inc. (NASDAQ:ALEC)

SG Americas Securities LLC reduced its holdings in shares of Alector, Inc. (NASDAQ:ALEC) by 52.1% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 30,753 shares of the company’s stock after selling 33,430 shares during the quarter. SG Americas Securities LLC’s holdings in Alector were worth $143,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of ALEC. Gladius Capital Management LP bought a new stake in shares of Alector during the 2nd quarter valued at $29,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Alector in the first quarter worth about $40,000. Lazard Asset Management LLC purchased a new stake in shares of Alector in the first quarter worth about $59,000. ProShare Advisors LLC boosted its position in shares of Alector by 24.1% in the first quarter. ProShare Advisors LLC now owns 19,709 shares of the company’s stock valued at $119,000 after acquiring an additional 3,827 shares during the period. Finally, Caxton Associates LP grew its stake in Alector by 41.3% during the second quarter. Caxton Associates LP now owns 20,282 shares of the company’s stock valued at $92,000 after acquiring an additional 5,933 shares in the last quarter. 85.83% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alector in a report on Tuesday, September 17th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $17.75.

Alector Price Performance

ALEC opened at $4.76 on Friday. The stock’s 50 day simple moving average is $5.08 and its 200 day simple moving average is $5.15. The firm has a market cap of $458.79 million, a price-to-earnings ratio of -3.45 and a beta of 0.68. Alector, Inc. has a 1 year low of $3.66 and a 1 year high of $8.90.

Alector (NASDAQ:ALEC) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. Alector had a negative return on equity of 102.63% and a negative net margin of 290.66%. The firm had revenue of $15.08 million during the quarter, compared to analyst estimates of $16.04 million. During the same quarter in the prior year, the firm posted $0.02 earnings per share. As a group, sell-side analysts anticipate that Alector, Inc. will post -1.92 EPS for the current year.

Insider Buying and Selling

In other Alector news, insider Sara Kenkare-Mitra sold 13,926 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $67,958.88. Following the completion of the transaction, the insider now owns 291,715 shares of the company’s stock, valued at $1,423,569.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Sara Kenkare-Mitra sold 13,926 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $67,958.88. Following the transaction, the insider now directly owns 291,715 shares of the company’s stock, valued at approximately $1,423,569.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Arnon Rosenthal sold 26,499 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $129,315.12. Following the transaction, the chief executive officer now owns 1,948,746 shares of the company’s stock, valued at approximately $9,509,880.48. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 58,222 shares of company stock valued at $286,013 over the last ninety days. 9.10% of the stock is owned by insiders.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.